{"id":"standard-dose-topiramate","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Cognitive impairment / memory problems"},{"rate":"20-30","effect":"Paresthesia"},{"rate":"10-15","effect":"Weight loss"},{"rate":"10-15","effect":"Fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"1-2","effect":"Acute myopia / angle-closure glaucoma"},{"rate":"1-5","effect":"Metabolic acidosis"}]},"_chembl":{"chemblId":"CHEMBL220492","moleculeType":"Small molecule","molecularWeight":"339.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topiramate works through multiple mechanisms: it stabilizes neuronal membranes by blocking voltage-gated sodium channels, potentiates the inhibitory neurotransmitter GABA at GABA-A receptors, and inhibits carbonic anhydrase enzymes. These combined effects reduce abnormal electrical activity in the brain, making it effective for seizure control and migraine prevention.","oneSentence":"Topiramate blocks sodium channels, enhances GABA activity, and inhibits carbonic anhydrase to reduce neuronal excitability and prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:01.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy / seizure disorders"},{"name":"Migraine prophylaxis"},{"name":"Bipolar disorder (off-label)"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT04572217","phase":"PHASE2","title":"Medications After Adolescent Bariatric Surgery","status":"WITHDRAWN","sponsor":"Janey Pratt","startDate":"2022-06-01","conditions":"Pediatric Obesity","enrollment":""},{"nctId":"NCT04095104","phase":"PHASE2","title":"Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-15","conditions":"Obesity, Morbid, Bariatric Surgery, Adolescent","enrollment":13},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT01765218","phase":"PHASE1, PHASE2","title":"Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy","status":"TERMINATED","sponsor":"Kristin R Hoffman","startDate":"2013-02","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":34},{"nctId":"NCT05403229","phase":"PHASE2","title":"The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-10-17","conditions":"Sudden Deafness, Sudden Sensorineural Hearing Loss","enrollment":140},{"nctId":"NCT00777218","phase":"NA","title":"Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine","status":"WITHDRAWN","sponsor":"University of South Alabama","startDate":"2007-08","conditions":"Migraine","enrollment":""},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01060111","phase":"PHASE4","title":"An Efficacy and Tolerability Study of Topiramate in Participants With Migraine","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2006-07","conditions":"Migraine","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard topiramate"],"phase":"marketed","status":"active","brandName":"Standard dose topiramate","genericName":"Standard dose topiramate","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topiramate blocks sodium channels, enhances GABA activity, and inhibits carbonic anhydrase to reduce neuronal excitability and prevent seizures. Used for Epilepsy / seizure disorders, Migraine prophylaxis, Bipolar disorder (off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}